Aurinia Pharmaceuticals (AUPH) Q1 2024 Annual Earnings
AUPH·Reported May 2, 2024·Before market open
Aurinia Pharmaceuticals reported Q1 2024 revenue of $50.3M, beat analyst consensus of $47.5M by $2.9M. Diluted EPS came in at $-0.03, beat the $-0.17 consensus by $0.14.
Revenue
$50.3Mbeat by $2.9M
Consensus: $47.5MDiluted EPS
$-0.03beat by $0.14
Consensus: $-0.17
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Aurinia Pharmaceuticals's Q1 2024 earnings report.
Aurinia Pharmaceuticals (AUPH) reported Q1 2024 earnings on May 2, 2024 before market open.
Aurinia Pharmaceuticals reported revenue of $50.3M and diluted EPS of $-0.03 for Q1 2024.
Revenue beat the consensus estimate of $47.5M by $2.9M. EPS beat the consensus estimate of $-0.17 by $0.14.
You can read the 10-K/A periodic report (0001600620-24-000041) directly on SEC EDGAR. The filing index links above go to sec.gov.